Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
The diagnosis of Alzheimer's disease can be improved by the use of biological measures.
Biomarkers of functional impairment, neuronal loss, and protein deposition that can be …
Biomarkers of functional impairment, neuronal loss, and protein deposition that can be …
[HTML][HTML] Radiopharmaceuticals for PET and SPECT imaging: a literature review over the last decade
G Crișan, NS Moldovean-Cioroianu… - International Journal of …, 2022 - mdpi.com
Positron emission tomography (PET) uses radioactive tracers and enables the functional
imaging of several metabolic processes, blood flow measurements, regional chemical …
imaging of several metabolic processes, blood flow measurements, regional chemical …
Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease
The recent development of tau-specific positron emission tomography (PET) tracers enables
in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease …
in vivo quantification of regional tau pathology, one of the key lesions in Alzheimer's disease …
[HTML][HTML] Tau PET imaging: present and future directions
Abnormal aggregation of tau in the brain is a major contributing factor in various
neurodegenerative diseases. The role of tau phosphorylation in the pathophysiology of …
neurodegenerative diseases. The role of tau phosphorylation in the pathophysiology of …
Entorhinal tau pathology, episodic memory decline, and neurodegeneration in aging
The medial temporal lobe (MTL) is an early site of tau accumulation and MTL dysfunction
may underlie episodic-memory decline in aging and dementia. Postmortem data indicate …
may underlie episodic-memory decline in aging and dementia. Postmortem data indicate …
[HTML][HTML] Biomarkers for tau pathology
The aggregation of fibrils of hyperphosphorylated and C-terminally truncated microtubule-
associated tau protein characterizes 80% of all dementia disorders, the most common …
associated tau protein characterizes 80% of all dementia disorders, the most common …
In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer disease dementia to young controls
Tau PET imaging has potential for elucidating changes in the deposition of
neuropathological tau aggregates that are occurring during the progression of Alzheimer …
neuropathological tau aggregates that are occurring during the progression of Alzheimer …
[HTML][HTML] Tauvid™: the first FDA-approved PET tracer for imaging tau pathology in Alzheimer's disease
Tauvid has been approved by the US Food and Drug Administration (FDA) in 2020 for
positron emission tomography (PET) imaging of adult patients with cognitive impairments …
positron emission tomography (PET) imaging of adult patients with cognitive impairments …
[HTML][HTML] Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development
SP McCluskey, C Plisson, EA Rabiner… - European journal of …, 2020 - Springer
Purpose A limit on developing new treatments for a number of central nervous system (CNS)
disorders has been the inadequate understanding of the in vivo pathophysiology underlying …
disorders has been the inadequate understanding of the in vivo pathophysiology underlying …
[HTML][HTML] PET neuroimaging of Alzheimer's disease: radiotracers and their utility in clinical research
W Bao, F Xie, C Zuo, Y Guan… - Frontiers in aging …, 2021 - frontiersin.org
Alzheimer's Disease (AD), the leading cause of senile dementia, is a progressive
neurodegenerative disorder affecting millions of people worldwide and exerting tremendous …
neurodegenerative disorder affecting millions of people worldwide and exerting tremendous …